AustralieFrV1, PascalFrancis, Curation, bibRecord, 003F20

Glycemic Thresholds for Diabetes-Specific Retinopathy: Implications for diagnostic criteria for diabetes

Identifieur interne : 003F20 ( PascalFrancis/Curation ); précédent : 003F19; suivant : 003F21

Glycemic Thresholds for Diabetes-Specific Retinopathy: Implications for diagnostic criteria for diabetes

Auteurs : Stephen Colagiuri [Australie] ; Crystal M. Y. Lee [Australie] ; Tien Y. Wong [Australie, Singapour] ; Beverley Balkau [France] ; Jonathan E. Shaw [Australie] ; Knut Borch-Johnsen [Danemark]

Source :

Diabetes care [ 0149-5992 ] ; 2011.

RBID : Pascal:11-0101199

Descripteurs français

Pascal (Inist)
- Diabète, Glycémie, Seuil, Rétinopathie, Diagnostic, Critère, Endocrinologie, Maladie métabolique, Nutrition, Homme.
Wicri :
- topic : Diabète, Nutrition, Homme.

English descriptors

KwdEn :
- Criterion, Diabetes mellitus, Diagnosis, Endocrinology, Glycemia, Human, Metabolic diseases, Nutrition, Retinopathy, Threshold.

Abstract

OBJECTIVE - To re-evaluate the relationship between glycemia and diabetic retinopathy. RESEARCH DESIGN AND METHODS - We conducted a data-pooling analysis of nine studies from five countries with 44,623 participants aged 20-79 years with gradable retinal photographs. The relationship between diabetes-specific retinopathy (defined as moderate or more severe retinopathy) and three glycemic measures (fasting plasma glucose [FPG; n = 41,411], 2-h post oral glucose load plasma glucose [2-h PG; n = 21,334], and AlC [n = 28,010]) was examined. RESULTS- When diabetes-specific retinopathy was plotted against continuous glycemic measures, a curvilinear relationship was observed for FPG and AlC. Diabetes-specific retinopathy prevalence was low for FPG <6.0 mmol/l and AlC <6.0% but increased above these levels. Based on vigintile (20 groups with equal numbers) distributions, glycemic thresholds for diabetes-specific retinopathy were observed over the range of 6.4-6.8 mmol/l for FPG, 9.8-10.6 mmol/l for 2-h PG, and 6.3-6.7% for AlC. Thresholds for diabetes-specific retinopathy from receiver-operating characteristic curve analyses were 6.6 mmol/l for FPG, 13.0 mmol/l for 2-h PG, and 6.4% for AlC. CONCLUSIONS - This study broadens the evidence based on diabetes diagnostic criteria. A narrow threshold range for diabetes-specific retinopathy was identified for FPG and AlC but not for 2-h PG. The combined analyses suggest that the current diabetes diagnostic level for FPG could be lowered to 6.5 mmol/l and that an AlC of 6.5% is a suitable alternative diagnostic criterion.

A01	`01`	`1`		`@0 0149-5992`
A02	`01`			`@0 DICAD2`
A03		`1`		`@0 Diabetes care`
A05				`@2 34`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Glycemic Thresholds for Diabetes-Specific Retinopathy: Implications for diagnostic criteria for diabetes`
A11	`01`	`1`		`@1 COLAGIURI (Stephen)`
A11	`02`	`1`		`@1 LEE (Crystal M. Y.)`
A11	`03`	`1`		`@1 WONG (Tien Y.)`
A11	`04`	`1`		`@1 BALKAU (Beverley)`
A11	`05`	`1`		`@1 SHAW (Jonathan E.)`
A11	`06`	`1`		`@1 BORCH-JOHNSEN (Knut)`
A14	`01`			`@1 Boden Institute of Obesity, Nutrition, and Exercise, University of Sydney @2 Sydney @3 AUS @Z 1 aut. @Z 2 aut.`
A14	`02`			`@1 Center for Eye Research Australia, University of Melbourne @2 Melbourne @3 AUS @Z 3 aut.`
A14	`03`			`@1 Singapore Eye Research Institute, National University of Singapore @3 SGP @Z 3 aut.`
A14	`04`			`@1 Institut National de la Santé et de la Recherche Médicale, Centre de Recherche en Epidémiologie et Santé des Populations, Epidemiology of Diabetes, Obesity, and Chronic Kidney Disease Over the Lifecourse @2 Villejuif @3 FRA @Z 4 aut.`
A14	`05`			`@1 Centre de Recherche en Epidémiologie et Santé des Populations, Université Paris Sud @2 Villejuif @3 FRA @Z 4 aut.`
A14	`06`			`@1 Heart and Diabetes Institute, Baker International Diabetes Institute @2 Melbourne @3 AUS @Z 5 aut.`
A14	`07`			`@1 Steno Diabetes Center @2 Gentofte @3 DNK @Z 6 aut.`
A14	`08`			`@1 Faculty of Health Science, University of Aarhus @2 Aarhus @3 DNK @Z 6 aut.`
A17	`01`	`1`		`@1 DETECT-2 COLLABORATION WRITING GROUP @3 INC`
A20				`@1 145-150`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18054 @5 354000193628710290`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 11-0101199`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Diabetes care`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 OBJECTIVE - To re-evaluate the relationship between glycemia and diabetic retinopathy. RESEARCH DESIGN AND METHODS - We conducted a data-pooling analysis of nine studies from five countries with 44,623 participants aged 20-79 years with gradable retinal photographs. The relationship between diabetes-specific retinopathy (defined as moderate or more severe retinopathy) and three glycemic measures (fasting plasma glucose [FPG; n = 41,411], 2-h post oral glucose load plasma glucose [2-h PG; n = 21,334], and AlC [n = 28,010]) was examined. RESULTS- When diabetes-specific retinopathy was plotted against continuous glycemic measures, a curvilinear relationship was observed for FPG and AlC. Diabetes-specific retinopathy prevalence was low for FPG <6.0 mmol/l and AlC <6.0% but increased above these levels. Based on vigintile (20 groups with equal numbers) distributions, glycemic thresholds for diabetes-specific retinopathy were observed over the range of 6.4-6.8 mmol/l for FPG, 9.8-10.6 mmol/l for 2-h PG, and 6.3-6.7% for AlC. Thresholds for diabetes-specific retinopathy from receiver-operating characteristic curve analyses were 6.6 mmol/l for FPG, 13.0 mmol/l for 2-h PG, and 6.4% for AlC. CONCLUSIONS - This study broadens the evidence based on diabetes diagnostic criteria. A narrow threshold range for diabetes-specific retinopathy was identified for FPG and AlC but not for 2-h PG. The combined analyses suggest that the current diabetes diagnostic level for FPG could be lowered to 6.5 mmol/l and that an AlC of 6.5% is a suitable alternative diagnostic criterion.
C02	`01`	`X`		`@0 002B21E01A`
C02	`02`	`X`		`@0 002B22`
C02	`03`	`X`		`@0 002B30A11`
C03	`01`	`X`	`FRE`	`@0 Diabète @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Diabetes mellitus @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Diabetes @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Glycémie @5 02`
C03	`02`	`X`	`ENG`	`@0 Glycemia @5 02`
C03	`02`	`X`	`SPA`	`@0 Glucemia @5 02`
C03	`03`	`X`	`FRE`	`@0 Seuil @5 03`
C03	`03`	`X`	`ENG`	`@0 Threshold @5 03`
C03	`03`	`X`	`SPA`	`@0 Umbral @5 03`
C03	`04`	`X`	`FRE`	`@0 Rétinopathie @5 04`
C03	`04`	`X`	`ENG`	`@0 Retinopathy @5 04`
C03	`04`	`X`	`SPA`	`@0 Retinopatía @5 04`
C03	`05`	`X`	`FRE`	`@0 Diagnostic @5 05`
C03	`05`	`X`	`ENG`	`@0 Diagnosis @5 05`
C03	`05`	`X`	`SPA`	`@0 Diagnóstico @5 05`
C03	`06`	`X`	`FRE`	`@0 Critère @5 06`
C03	`06`	`X`	`ENG`	`@0 Criterion @5 06`
C03	`06`	`X`	`SPA`	`@0 Criterio @5 06`
C03	`07`	`X`	`FRE`	`@0 Endocrinologie @5 08`
C03	`07`	`X`	`ENG`	`@0 Endocrinology @5 08`
C03	`07`	`X`	`SPA`	`@0 Endocrinología @5 08`
C03	`08`	`X`	`FRE`	`@0 Maladie métabolique @5 09`
C03	`08`	`X`	`ENG`	`@0 Metabolic diseases @5 09`
C03	`08`	`X`	`SPA`	`@0 Metabolismo patología @5 09`
C03	`09`	`X`	`FRE`	`@0 Nutrition @5 11`
C03	`09`	`X`	`ENG`	`@0 Nutrition @5 11`
C03	`09`	`X`	`SPA`	`@0 Nutrición @5 11`
C03	`10`	`X`	`FRE`	`@0 Homme @5 25`
C03	`10`	`X`	`ENG`	`@0 Human @5 25`
C03	`10`	`X`	`SPA`	`@0 Hombre @5 25`
C07	`01`	`X`	`FRE`	`@0 Endocrinopathie @5 37`
C07	`01`	`X`	`ENG`	`@0 Endocrinopathy @5 37`
C07	`01`	`X`	`SPA`	`@0 Endocrinopatía @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'oeil @5 38`
C07	`02`	`X`	`ENG`	`@0 Eye disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Ojo patología @5 38`
N21				`@1 066`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002013

Links to Exploration step

Pascal:11-0101199

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Glycemic Thresholds for Diabetes-Specific Retinopathy: Implications for diagnostic criteria for diabetes</title>
<author><name sortKey="Colagiuri, Stephen" sort="Colagiuri, Stephen" uniqKey="Colagiuri S" first="Stephen" last="Colagiuri">Stephen Colagiuri</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Boden Institute of Obesity, Nutrition, and Exercise, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Lee, Crystal M Y" sort="Lee, Crystal M Y" uniqKey="Lee C" first="Crystal M. Y." last="Lee">Crystal M. Y. Lee</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Boden Institute of Obesity, Nutrition, and Exercise, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Wong, Tien Y" sort="Wong, Tien Y" uniqKey="Wong T" first="Tien Y." last="Wong">Tien Y. Wong</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Center for Eye Research Australia, University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Singapore Eye Research Institute, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Balkau, Beverley" sort="Balkau, Beverley" uniqKey="Balkau B" first="Beverley" last="Balkau">Beverley Balkau</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institut National de la Santé et de la Recherche Médicale, Centre de Recherche en Epidémiologie et Santé des Populations, Epidemiology of Diabetes, Obesity, and Chronic Kidney Disease Over the Lifecourse</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Centre de Recherche en Epidémiologie et Santé des Populations, Université Paris Sud</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E." last="Shaw">Jonathan E. Shaw</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Heart and Diabetes Institute, Baker International Diabetes Institute</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Borch Johnsen, Knut" sort="Borch Johnsen, Knut" uniqKey="Borch Johnsen K" first="Knut" last="Borch-Johnsen">Knut Borch-Johnsen</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Steno Diabetes Center</s1>
<s2>Gentofte</s2>
<s3>DNK</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Danemark</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Faculty of Health Science, University of Aarhus</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Danemark</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0101199</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0101199 INIST</idno>
<idno type="RBID">Pascal:11-0101199</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002013</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003F20</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Glycemic Thresholds for Diabetes-Specific Retinopathy: Implications for diagnostic criteria for diabetes</title>
<author><name sortKey="Colagiuri, Stephen" sort="Colagiuri, Stephen" uniqKey="Colagiuri S" first="Stephen" last="Colagiuri">Stephen Colagiuri</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Boden Institute of Obesity, Nutrition, and Exercise, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Lee, Crystal M Y" sort="Lee, Crystal M Y" uniqKey="Lee C" first="Crystal M. Y." last="Lee">Crystal M. Y. Lee</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Boden Institute of Obesity, Nutrition, and Exercise, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Wong, Tien Y" sort="Wong, Tien Y" uniqKey="Wong T" first="Tien Y." last="Wong">Tien Y. Wong</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Center for Eye Research Australia, University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Singapore Eye Research Institute, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Balkau, Beverley" sort="Balkau, Beverley" uniqKey="Balkau B" first="Beverley" last="Balkau">Beverley Balkau</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institut National de la Santé et de la Recherche Médicale, Centre de Recherche en Epidémiologie et Santé des Populations, Epidemiology of Diabetes, Obesity, and Chronic Kidney Disease Over the Lifecourse</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Centre de Recherche en Epidémiologie et Santé des Populations, Université Paris Sud</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E." last="Shaw">Jonathan E. Shaw</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Heart and Diabetes Institute, Baker International Diabetes Institute</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Borch Johnsen, Knut" sort="Borch Johnsen, Knut" uniqKey="Borch Johnsen K" first="Knut" last="Borch-Johnsen">Knut Borch-Johnsen</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Steno Diabetes Center</s1>
<s2>Gentofte</s2>
<s3>DNK</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Danemark</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Faculty of Health Science, University of Aarhus</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Danemark</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Diabetes care</title>
<title level="j" type="abbreviated">Diabetes care</title>
<idno type="ISSN">0149-5992</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Diabetes care</title>
<title level="j" type="abbreviated">Diabetes care</title>
<idno type="ISSN">0149-5992</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Criterion</term>
<term>Diabetes mellitus</term>
<term>Diagnosis</term>
<term>Endocrinology</term>
<term>Glycemia</term>
<term>Human</term>
<term>Metabolic diseases</term>
<term>Nutrition</term>
<term>Retinopathy</term>
<term>Threshold</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Diabète</term>
<term>Glycémie</term>
<term>Seuil</term>
<term>Rétinopathie</term>
<term>Diagnostic</term>
<term>Critère</term>
<term>Endocrinologie</term>
<term>Maladie métabolique</term>
<term>Nutrition</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Diabète</term>
<term>Nutrition</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">OBJECTIVE - To re-evaluate the relationship between glycemia and diabetic retinopathy. RESEARCH DESIGN AND METHODS - We conducted a data-pooling analysis of nine studies from five countries with 44,623 participants aged 20-79 years with gradable retinal photographs. The relationship between diabetes-specific retinopathy (defined as moderate or more severe retinopathy) and three glycemic measures (fasting plasma glucose [FPG; n = 41,411], 2-h post oral glucose load plasma glucose [2-h PG; n = 21,334], and AlC [n = 28,010]) was examined. RESULTS- When diabetes-specific retinopathy was plotted against continuous glycemic measures, a curvilinear relationship was observed for FPG and AlC. Diabetes-specific retinopathy prevalence was low for FPG <6.0 mmol/l and AlC <6.0% but increased above these levels. Based on vigintile (20 groups with equal numbers) distributions, glycemic thresholds for diabetes-specific retinopathy were observed over the range of 6.4-6.8 mmol/l for FPG, 9.8-10.6 mmol/l for 2-h PG, and 6.3-6.7% for AlC. Thresholds for diabetes-specific retinopathy from receiver-operating characteristic curve analyses were 6.6 mmol/l for FPG, 13.0 mmol/l for 2-h PG, and 6.4% for AlC. CONCLUSIONS - This study broadens the evidence based on diabetes diagnostic criteria. A narrow threshold range for diabetes-specific retinopathy was identified for FPG and AlC but not for 2-h PG. The combined analyses suggest that the current diabetes diagnostic level for FPG could be lowered to 6.5 mmol/l and that an AlC of 6.5% is a suitable alternative diagnostic criterion.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0149-5992</s0>
</fA01>
<fA02 i1="01"><s0>DICAD2</s0>
</fA02>
<fA03 i2="1"><s0>Diabetes care</s0>
</fA03>
<fA05><s2>34</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Glycemic Thresholds for Diabetes-Specific Retinopathy: Implications for diagnostic criteria for diabetes</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>COLAGIURI (Stephen)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LEE (Crystal M. Y.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>WONG (Tien Y.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BALKAU (Beverley)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SHAW (Jonathan E.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BORCH-JOHNSEN (Knut)</s1>
</fA11>
<fA14 i1="01"><s1>Boden Institute of Obesity, Nutrition, and Exercise, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Center for Eye Research Australia, University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Singapore Eye Research Institute, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Institut National de la Santé et de la Recherche Médicale, Centre de Recherche en Epidémiologie et Santé des Populations, Epidemiology of Diabetes, Obesity, and Chronic Kidney Disease Over the Lifecourse</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Centre de Recherche en Epidémiologie et Santé des Populations, Université Paris Sud</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Heart and Diabetes Institute, Baker International Diabetes Institute</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Steno Diabetes Center</s1>
<s2>Gentofte</s2>
<s3>DNK</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Faculty of Health Science, University of Aarhus</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>DETECT-2 COLLABORATION WRITING GROUP</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>145-150</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18054</s2>
<s5>354000193628710290</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0101199</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Diabetes care</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>OBJECTIVE - To re-evaluate the relationship between glycemia and diabetic retinopathy. RESEARCH DESIGN AND METHODS - We conducted a data-pooling analysis of nine studies from five countries with 44,623 participants aged 20-79 years with gradable retinal photographs. The relationship between diabetes-specific retinopathy (defined as moderate or more severe retinopathy) and three glycemic measures (fasting plasma glucose [FPG; n = 41,411], 2-h post oral glucose load plasma glucose [2-h PG; n = 21,334], and AlC [n = 28,010]) was examined. RESULTS- When diabetes-specific retinopathy was plotted against continuous glycemic measures, a curvilinear relationship was observed for FPG and AlC. Diabetes-specific retinopathy prevalence was low for FPG <6.0 mmol/l and AlC <6.0% but increased above these levels. Based on vigintile (20 groups with equal numbers) distributions, glycemic thresholds for diabetes-specific retinopathy were observed over the range of 6.4-6.8 mmol/l for FPG, 9.8-10.6 mmol/l for 2-h PG, and 6.3-6.7% for AlC. Thresholds for diabetes-specific retinopathy from receiver-operating characteristic curve analyses were 6.6 mmol/l for FPG, 13.0 mmol/l for 2-h PG, and 6.4% for AlC. CONCLUSIONS - This study broadens the evidence based on diabetes diagnostic criteria. A narrow threshold range for diabetes-specific retinopathy was identified for FPG and AlC but not for 2-h PG. The combined analyses suggest that the current diabetes diagnostic level for FPG could be lowered to 6.5 mmol/l and that an AlC of 6.5% is a suitable alternative diagnostic criterion.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B21E01A</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B22</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B30A11</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Diabète</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Diabetes mellitus</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Diabetes</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Glycémie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Glycemia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Glucemia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Seuil</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Threshold</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Umbral</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Rétinopathie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Retinopathy</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Retinopatía</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Diagnostic</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Diagnosis</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Diagnóstico</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Critère</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Criterion</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Criterio</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Endocrinologie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Endocrinology</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Endocrinología</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Maladie métabolique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Metabolic diseases</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Metabolismo patología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Nutrition</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Nutrition</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Nutrición</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>25</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>25</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>25</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Endocrinopathie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Endocrinopathy</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Endocrinopatía</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'oeil</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Eye disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Ojo patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>066</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F20 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 003F20 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:11-0101199
   |texte=   Glycemic Thresholds for Diabetes-Specific Retinopathy: Implications for diagnostic criteria for diabetes
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Glycemic Thresholds for Diabetes-Specific Retinopathy: Implications for diagnostic criteria for diabetes

Glycemic Thresholds for Diabetes-Specific Retinopathy: Implications for diagnostic criteria for diabetes

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri